

Intestinal obstruction due to idiopathic sclerosing encapsulating peritonitis. Clinical report and review of literature

V. MINUTOLO^{1,2}, G. GAGLIANO², G. ANGRILLO², O. MINUTOLO²,
A. MORELLO³, C. RINZIVILLO¹

SUMMARY: Intestinal obstruction due to idiopathic sclerosing encapsulating peritonitis. Clinical report and review of literature.

V. MINUTOLO, G. GAGLIANO, G. ANGRILLO, O. MINUTOLO,
A. MORELLO, C. RINZIVILLO

The sclerosing peritonitis (SP) is a rare illness secondary to the peritoneal dialysis or due to intraperitoneal chemotherapy or the positioning of a peritoneal-jugular shunt in cirrhotic patient with refractory ascites or due to unknown other factors (idiopathic form) like in our patient.

The clinical pattern is various and insidious, but when an intestinal occlusive symptomatology is presents an urgent operation is mandatory. The surgical operation is often not easy and asks for a lot of attention especially in the dialyzed subject or in patients with cirrhosis, due to the possibility of postoperative bleeding and other serious complications that can result fatal.

In this report we describe surgical treatment, pathologic pattern and clinical findings of this rare disease.

RIASSUNTO: Occlusione intestinale da peritonite sclerosante idiopatica incapsulante. Caso clinico e rassegna della letteratura.

V. MINUTOLO, G. GAGLIANO, G. ANGRILLO, O. MINUTOLO,
A. MORELLO, C. RINZIVILLO

La peritonite sclerosante è una condizione patologica rara, solitamente secondaria a dialisi peritoneale o a chemioterapia intraperitoneale o ancora dovuta al posizionamento di uno shunt peritoneo-giugulare in pazienti cirrotici con ascite refrattaria al trattamento; può essere causata anche da altri e ignoti fattori (forma idiopatica), come nel caso qui descritto per il quale si può pensare ad una predisposizione genetica.

Il quadro clinico è variabile e insidioso, ma quando compare una sintomatologia occlusiva si impone l'intervento, che spesso non è semplice e anzi richiede una speciale attenzione nei pazienti dializzati o cirrotici, per la possibilità di emorragie e altre gravi complicanze che possono condurre all'exitus.

Descriviamo il trattamento chirurgico e il quadro istologico e clinico di un caso giunto alla nostra osservazione.

KEY WORDS: Idiopathic sclerosing peritonitis - Intestinal obstruction - Surgery.
Peritonite idiopatica sclerosante - Occlusione intestinale - Chirurgia.

Introduction

Peritonitis, both primitive and secondary, still presents high elevated morbidity and mortality despite the notable progress about the physiopathologic knowledge. Encapsulating Sclerosing Peritonitis (SP) is a severe kind of peritonitis, relatively frequent in subjects

submitted to peritoneal dialysis during at least 5 years or, rarely, in subjects that received chemohypertermic intraperitoneal perfusion (1-18).

Its physiopathologic mechanisms are today still unknown even if recently some Authors suggest that the Connective Tissue Growth Factor (CTGF) can be responsible of the development of peritoneal fibrosclerosis, through the mediation of the Transforming Growth Factor-Beta 1 (TGF- β 1) (1).

The evolution of post-dialytic peritonitis is characterized by the onset of fibrosis and abdominal adhesions; these play an important role in the pathogenesis of chronic abdominal-pelvic pain and they constitute the most frequent cause of intestinal obstruction.

We observed a patient suffering from intestinal obstruction due to idiopathic encapsulating SP. The patient had not undergone dialysis neither submitted to

Università degli Studi di Catania

¹ Dipartimento Scienze Chirurgiche, Trapianti d'Organo e Tecnologie Avanzate (Direttore: Prof. A. Licata)

² Ospedale di Vittoria (RG), Italy
Divisione Clinicizzata Chirurgia Generale (Direttore: Prof. V. Minutolo)

³ Università degli Studi di Catania
Dipartimento Scienze Microbiologiche e Ginecologiche (Direttore: Prof. G. Tempera)

© Copyright 2008, CIC Edizioni Internazionali, Roma

intraperitoneal chemotherapy and therefore we hypothesize to other unknown etiologic factors.

Case report

C. B., 45 years old male, operated for Fallot's tetralogy twenty years before and for left inguinal hernia three years before. From four years he suffered colic pain, diffused to all abdominal quadrants and abdominal tension. Four months before he was admitted to a Department of Cardiology for cardiac failure and ascites.

At admission the patient presents symptoms of intestinal obstruction. The rectum was empty at the rectal touch. Laboratory findings showed neutrophilia, alteration of serum electrolytes (Na 131; Cl 94; Ca 8.7). Direct Rx abdominal examination showed relevant liquid and gaseous levels. Ultrasound abdominal examinations revealed the presence of free liquid into Douglas' space and thickened walls of the ileum. Chest x-Rays showed a diffused congestive bronchial reinforcement, congestion of pulmonary hila and a very increased cardiac shade.

Laparotomy is planned and performed without a precise diagnosis. The peritoneal wall appeared thickened and duodenum, ileum, right colon and a part of the transverse colon were enormously dilated and covered and englobed by a thickened membrane. At the parietocolic grooves and among some intestinal loops serous polycystic formations were present. A partial resection of the tickened layer has been performed (with dissection of all involved intestinal loops) and debulking of the cystic lesion; no intestinal resection has been necessary.

In the postoperative period the patient presented no problems; canalization to gas happened after 48 hours and to faeces after 4 days. The patient has been discharged after 9 days.

The histological examination revealed laminar fragments of fibrosclerotic tissue and cystic angiomatous-like formations of mesothelial derivation in zone areas associated with fibro-scleroproductive chronic inflammation.

Discussion

Incapsulated idiopathic SP was described for the first time by Owtshinnikov (1907); it's a rare and dangerous pathology of the peritoneum. It's characterized by the presence of a fibrous tissue, thickened and with white-grey tinges, that covers and englobes the intestinal loops, determining serious complications as obstruction, necrosis, gut-skin fistulas, malnutrition, ascites (19-23) with possibility of generalized sclerosis (24).

Mortality rate is relevant, up to 60% within 4 months from the diagnosis (25). Rarely, a fulminant SP is immediately following an acute bacterial peritonitis (26) or SP presents itself in liver transplant patients (27) or during familial mediterranean fever (28) or after intestinal transplant in child (29) or during cirrhosis (30), but also during fatal mycotic peritonitis in humans (6) or post-leishmaniasis in a dog-model (31). In another animal model (rats) activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis (18). Other clinical factors can

be the immission in the peritoneum of sterilizing chemical mediums or tampons or catheters or drugs into dialyzing liquids and others substances (32).

Among the not dialysis-dependent factors that allow the onset of the SP, there are betablocker drugs, tumors, genetic predisposition, umbilical hernias, previous abdominal operations, gallbladder disorders (33, 34). Other factors or pathologic mechanisms can be epithelial-mesenchymal transition (9) or hypertrophic mesothelium (35) or advanced (hyper-)glycation end-products (36) or intracellular pH changes (induced by sclerosing drugs) in peritoneal fibroblasts (37).

The encapsulating SP, characterized by a tickening of the peritoneal membrane, is complicated by occlusion and in the dialytic patient it presents an incidence ranging from 0,7% up to 0,9% (32). After insertion of Le Veen's valve in patients with cirrhosis and ascites the incidence is up to 38% but to 17% if we consider the obstructed ones (38). Gerunda and coll. (33) reported an incidence of 8% for symptomatic patients with patterns of intestinal obstruction.

From the pathologic point of view the intestinal loops appear covered by a thickened membrane, shining and whitish, that determines stiffness in the organs involved forming tumor-like masses containing ileal loops and ascites. Microscopically the principal pattern is a homogeneously distributed sclerosis (39). There is a compression of the muscular layers with fibroblastic and mesoblastic cell infiltrates and it's often presents a cellular infiltration of leukocytes, red blood cells, macrophags and giant cells also, like in the our case.

An important question is if fibrosis and sclerosis are different disorders or different stages (39); for this kind of pathophysiologic study, PET-imaging becomes very useful (40).

The symptoms associated with the incapsulated SP are several: anorexia, nausea, vomiting, diarrhea, constipation, abdominal tension, fever, loss of muscular mass, abdominal pain, abdominal palpable mass, intestinal obstruction.

The diagnosis is obtained by abdominal direct Rx examination with the presence of the levels or by ultrasound and CT or MRI (41), that show the tickening of the intestinal wall, the evidence of picked and forced ileal loops into abdominal central region and the presence of pluricystic ascites. These signs confirm the diagnosis of incapsulated SP. It's very interesting the observation of 'peritoneal/mesenteric ossification' by CT-scans (42, 43).

Nevertheless some experiences with medical therapy (44-47), the treatment of advanced forms and especially of complications is surgical and consists in dissecting the fibrous layers from intestinal loops. In the cirrhotic or dialyzed patients mortality is elevated rather than in

patient without such pathological conditions as in our case (resolved without any complications).

Conclusions

The incapsulating SP is a rare illness secondary to the peritoneal dialysis or due to the positioning of a peritoneal-jugular shunt in cirrhotic patient with re-

fractory ascites or due to unknown other factors like in our patient. In the case described, the etiology can be attributed to a genetic predisposition.

The clinical pattern is various and insidious, but when an occlusive symptomatology is presents an urgent operation is mandatory; the surgical operation is often not easy, especially in the dialyzed subject or in patients with cirrhosis, due to the possibility of bleeding and serious complications that can result fatal.

References

1. Mitaritunno M, Occhionorelli S, De Tullio D, Pollini V, Fonte V. Sclerosing encapsulating peritonitis: a rare complication of peritoneal dialysis. A case report. *Chir Ital.* 2002, 54 (1): 87-90.
2. Poultsidi A, Liakopoulos V, Eleftheriadis T, Zarogiannis S, Bouchlariotou S, Stefanidis I. Gross calcification of the small bowel in a continuous ambulatory peritoneal dialysis patient with sclerosing peritonitis. *Adv Perit Dial.* 2006;22:104-7.
3. Selgas R, Bajo A, Jimenez-Heffernan JA, Sanchez-Tomero JA, Del Peso G, Aguilera A, Lopez-Cabrera M. Epithelial-to-mesenchymal transition of the mesothelial cell-its role in the response of the peritoneum to dialysis. *Nephrol Dial Transplant.* 2006 Jul;21 Suppl 2:ii2-7.
4. Eltoum MA, Wright S, Atchley J, Mason JC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. *Perit Dial Int.* 2006 Mar-Apr;26(2):203-6.
5. Scanziani R, Pozzi M, Pisano L, Santagostino Barbone G, Dozio B, Rovere G, Gabella P, Magri F. Imaging work-up for peritoneal access care and peritoneal dialysis complications. *Int J Artif Organs.* 2006 Jan;29(1):142-52.
6. Gupta A, Mi H, Wroe C, Jaques B, Talbot D. Fatal *Candida famata* peritonitis complicating sclerosing peritonitis in a peritoneal dialysis patient. *Nephrol Dial Transplant.* 2006 Jul;21(7):2036-7.
7. Serafimidis C, Katsarolis I, Vernadakis S, Rallis G, Giannopoulos G, Legakis N, Peros G. Idiopathic sclerosing encapsulating peritonitis (or abdominal cocoon). *BMC Surg.* 2006 Feb 13;6:3.
8. Tan FL, Loh D, Prabhakaran K. Sclerosing encapsulating peritonitis in a child secondary to peritoneal dialysis. *J Pediatr Surg.* 2005 May;40(5).
9. Tan FL, Loh D, Prabhakaran K. Sclerosing encapsulating peritonitis in a child secondary to peritoneal dialysis. *J Pediatr Surg.* 2005 May;40(5).
10. Aguilera A, Yanez-Mo M, Selgas R, Sanchez-Madrid F, Lopez-Cabrera M. Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. *Curr Opin Investig Drugs.* 2005 Mar;6(3):262-8.
11. von Schnakenburg C, Pohl M, Haffner K, Zimmerhackl LB, Brandis M. [Sclerosing peritonitis without reduced ultrafiltration as complication of peritoneal dialysis] *Klin Padiatr.* 2005 Jan-Feb;217(1):41-4.
12. Evrenkaya TR, Atasoyu EM, Unver S, Basekim C, Baloglu H, Tulbek MY. Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis. *Nephrol Dial Transplant.* 2004 Sep;19(9):2423-4.
13. Kim BS, Choi HY, Ryu DR, Yoo TH, Park HC, Kang SW, Choi KH, Ha SK, Han DS, Lee HY. Clinical characteristics of dialysis related sclerosing encapsulating peritonitis: multi-center experience in Korea. *Yonsei Med J.* 2005 Feb 28;46(1):104-11.
14. Aihara H, Maruoka H, Kiyozaki H, Konishi F. Sclerosing encapsulating peritonitis (SEP) as a delayed complication of continuous hyperthermic peritoneal perfusion (CHPP): report of a case. *Surg Today.* 2003;33(3):232-6.
15. Pearson S, Jackson MA, Rylance PB. Sclerosing peritonitis complicating continuous ambulatory peritoneal dialysis managed by hemodialysis and home parenteral nutrition. *Clin Nephrol.* 2002 Sep;58(3):244-6.
16. Hoshii S, Honda M, Itami N, Oh S, Matsumura C, Moriya S, Mori M, Hatae K, Ito Y, Karashima S. Sclerosing encapsulating peritonitis in pediatric peritoneal dialysis patients. *Pediatr Nephrol.* 2000 Apr;14(4):275-9.
17. Hirahara I, Ogawa Y, Kusano E, Asano Y. Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats. *Nephrol Dial Transplant.* 2004 Jul;19(7): 1732-41.
18. Aihara H, Maruoka H, Kiyozaki H, Konishi F. Sclerosing encapsulating peritonitis (SEP) as a delayed complication of continuous hyperthermic peritoneal perfusion (CHPP): report of a case. *Surg Today.* 2003, 33 (3): 232-6.
19. Grefberg N, Nilsson P, Andreen T. Sclerosing obstructive peritonitis, beta-blockers and continuous ambulatory peritoneal dialysis. *Lancet.* 1983;2:733-4.
20. Kittur D, Korpe S, Raytch R, Smith G. Surgical aspects of sclerosing encapsulating peritonitis. *Arch Surg.* 1990;125: 1626-8.
21. Carcano G, Rovera F, Boni L, Dionigi G, Uccella L, Dionigi R. Idiopathic sclerosing encapsulating peritonitis: a case report. *Chir Ital.* 2003; 55(4): 605-608.
22. Chalasani R, Marella P. Sclerosing encapsulating peritonitis in a 47-year-old woman. *Kidney Int.* 2006 Nov;70(10):1673.
23. Pepels MJ, Peters FP, Mebis JJ, Ceelen TL, Hoofwijk AG, Erdkamp FL. Sclerosing peritonitis: an unusual cause of ascites in a patient with systemic lupus erythematosus. *Neth J Med.* 2006 Oct;64(9):346-9.
24. Basic-Jukic N, Kes P. Does sclerosing peritonitis induce MIA syndrome and generalized sclerosis? *Perit Dial Int.* 2005 Nov-Dec;25(6):608-10.
25. Slingeneyer A. Preliminary report on a co-operative international

- nal study in sclerosing encapsulating peritonitis. *Contrib Nephrol.* 1987;57:239-47.
26. Courtney AE, Doherty CC. Fulminant sclerosing peritonitis immediately following acute bacterial peritonitis. *Nephrol Dial Transplant.* 2006 Feb;21(2):532-4.
 27. Lin CH, Yu JC, Chen TW, Chan DC, Chen CJ, Hsieh CB. Sclerosing encapsulating peritonitis in a liver transplant patient: a case report. *World J Gastroenterol.* 2005 Sep 14;11(34):5412-3.
 28. Dabak R, Uygur-Bayramicli O, Aydin DK, Dolapcioglu C, Gemici C, Erginel T, Turan C, Karadayi N. Encapsulating peritonitis and familial Mediterranean fever. *World J Gastroenterol.* 2005 May 14;11(18):2844-6. Review.
 29. Macedo C, Sindhi R, Mazariegos GV, Abu-Elmagd K, Bond GJ, Reyes J. Sclerosing peritonitis after intestinal transplantation in children. *Pediatr. Transplant.* 2005 Apr;9(2):187-91.
 30. Yamamoto S, Sato Y, Takeishi T, Kobayashi T, Hatakeyama K. Sclerosing encapsulating peritonitis in two patients with liver cirrhosis. *J Gastroenterol.* 2004;39(2):172-5.
 31. Adamama-Moraitou KK, Prassinou NN, Patsikas MN, Psychas V, Tsioli B, Rallis TS. Sclerosing encapsulating peritonitis in a dog with leishmaniasis. *J Small Anim Pract.* 2004 Feb;45(2):117-21.
 32. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. *Am J Kidney Dis.* 1996; 28: 420-27.
 33. Gerunda G.E., Merenda R., Barbazza F, Zangrandi F, Valmasoni M., Margani G., Gagliesi A., Luongo B., Marano S., Menegon P., Maffei Faccioli A. La peritonite sclerosante incapsulante. *Atti Soc It Chir.* 2003;2: 340-352.
 34. Cancarini Gc, Sandrini M., Vizzardi V., Bertoli S., Buzzi L., Maiorca I. Clinical aspects of peritoneal sclerosis. *J Nephrol.* 2001; 14(4): 539-47.
 35. Bajo MA, del Peso G, Castro MA, Cirugeda A, Castro MJ, Olea T, Costero O, Sanchez-Tomero JA, Diaz C, Selgas R. Pathogenic significance of hypertrophic mesothelial cells in peritoneal effluent and ex vivo culture. *Adv Perit Dial.* 2004;20:43-6.
 36. Nakamura S, Niwa T. Advanced glycation end-products and peritoneal sclerosis. *Semin Nephrol.* 2004 Sep;24(5):502-5. Review.
 37. Soria M, Arrieta J, Ugarte I, Moina I, Guerra M, Escanero J. Intracellular pH changes induced by sclerosing agents in peritoneal fibroblasts. *Nefrologia.* 2004;24(2):158-66.
 38. Dobbie JW. Ultrastructure and pathology of the peritoneum in peritoneal dialysis. In: Gokal R, Nolph Kd (eds): *The Textbook of peritoneal dialysis.* Dordrecht: Kluwer Academic, 1994 : 17-44.
 39. Garosi G, Cappelletti F, Di Paolo N. Fibrosis and sclerosis: different disorders or different stages? *Contrib. Nephrol.* 2006;150:62-9. Review.
 40. Tarzi RM, Frank JW, Ahmad S, Levy JB, Brown EA. Fluorodeoxyglucose positron emission tomography detects the inflammatory phase of sclerosing peritonitis. *Perit Dial Int.* 2006 Mar-Apr;26(2):224-30.
 41. Huser N, Stangl M, Lutz J, Fend F, Kreyman B, Gaa J. Sclerosing encapsulating peritonitis: MRI diagnosis. *Eur Radiol.* 2006 Jan;16(1):238-9. Epub 2005 Apr 9.
 42. Kirchner J, Kickuth R, Stein A, Kirchner EM. Mesenteric ossification in CT indicates sclerosing peritonitis in chronic bacterial infection and pancreatitis. *Rontgenpraxis.* 2003;55(3): 99-102.
 43. Di Paolo N, Sacchi G, Lorenzoni P, Sansoni E, Gaggiotti E. Ossification of the peritoneal membrane. *Perit Dial Int.* 2004 Sep-Oct;24(5):471-7.
 44. Bianco R, de Rosa G, Staibano S, Somma P, Bianco AR. Ovarian luteinized thecoma with sclerosing peritonitis in an adult woman treated with leuprolide and toremifene in complete remission at 5 years. *Gynecol Oncol.* 2005 Mar;96(3):846-9.
 45. del Peso G, Bajo MA, Gil F, Aguilera A, Ros S, Costero O, Castro MJ, Selgas R. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. *Adv Perit Dial.* 2003;19:32-5.
 46. Rajani R, Smyth J, Koffman CG, Abbs I, Goldsmith DJ. Differential Effect of sirolimus vs prednisolone in the treatment of sclerosing encapsulating peritonitis. *Nephrol Dial Transplant.* 2002 Dec;17(12):2278-80.
 47. Martins LS, Rodrigues AS, Cabrita AN, Guimaraes S. Sclerosing encapsulating peritonitis: a case successfully treated with immunosuppression. *Perit Dial Int.* 1999 Sep-Oct;19(5): 478-81.